Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

June 13 (Reuters) - Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron Pharmaceuticals’ REGN.O offer for the DNA-testing company ...

Former 23andMe CEO Anne Wojcicki outbids Regeneron with a $305 million offer through her nonprofit TTAM to regain control of the DNA-testing company she co-founded.

Former 23andMe CEO Anne Wojcicki is set to regain control of the genetic testing firm she led to bankruptcy after outbidding a pharmaceutical company at an auction. The sale came on Monday after a ...

A nonprofit run by Anne Wojcicki, the cofounder and former CEO of 23andme, has agreed to buy the genetic testing company for ...

Anne Wojcicki, co-founder and former CEO of 23andMe, is set to regain control of the DNA-testing company after a nonprofit ...

23andMe's co-founder and former chief executive, Anne Wojcicki, looks set to regain control of the business after emerging ...

Anne Wojcicki won a bid to purchase the genetic testing platform through her nonprofit TTAM Research Institute. The $305M deal was part of a bankruptcy auction, beating out offers from Regeneron ...

Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron ...

Regeneron agreed to buy the firm for $256 million, topping a $146 million bid from Wojcicki and TTAM Research Institute. "The ...

Regeneron is backing away from buying the DNA-testing company after a nonprofit controlled by co-founder Wojcicki made a ...

Me could be back in the hands of former CEO Anne Wojcicki after her nonprofit offered $305 million to buy the company.